Skip to content
value.today

ImmunoCellular Therapeutics, Ltd.

Total raised
$13 M
3 rounds on record
Latest round
$8 M
Feb 2011
First round on record
Mar 2010
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of ImmunoCellular Therapeutics, Ltd.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2011$8 MNo. 3$2 to $10 million

ImmunoCellular Therapeutics, Ltd.: Raise no. 3, Feb 2011

Investors in this round

41 investors had bought by the notice of Mar 11, 2011: 41 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them, other: Unit consisting of 1 share of common stock and warrant for .5 share of common stock.
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$566,345
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • C. Kirk Peacock · Executive Officer
  • James Kirk Bender · Executive Officer
  • Manish Singh · Executive Officer, Director
  • Jacqueline Kirk Brandwynne · Director
  • John S. Yu · Director
  • Navdeep A. Jaikaria · Director
  • Rahul A. Singhvi · Director
  • Richard A. Cowell · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Summer Street Research Partners (CRD 127142) · Boston, MassachusettsSold in AL, AZ, CA, CO, CT, IL, MA, NJ, NY, PA, TN, TX
  • Dawson James Securities, Inc. (CRD 130645) · Boca Raton, FloridaSold in AL, AZ, CA, CO, CT, IL, MA, NJ, NY, PA, TN, TX

Remarks in the notice

  • On fees: “Sales commission consisted of $566,345 and 5 year warrants to purchase aggregate of 208,791 shares of common stock at exercise price of $2.25.”
  • On the use of proceeds: “All of the proceeds are being added to issuer's working capital which may in the future be used to pay salaries and fees of officers and directors.”

Signed by C. Kirk Peacock, Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 11, 2011. Read the notice at the SEC.

equitySEC
May 2010$3 MNo. 2$2 to $10 million

ImmunoCellular Therapeutics, Ltd.: Raise no. 2, May 2010

Investors in this round

12 investors had bought by the notice of Jun 3, 2010: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them, other: Sold in units with each unit consisting of 1 share of common stock and warrant for .5 share of common stock.
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
$46,550
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • C. Kirk Peacock · Executive Officer
  • James Kirk Bender · Executive Officer
  • Manish Singh · Executive Officer, Director
  • Jacqueline Kirk Brandwynne · Director
  • John L. Yu · Director
  • Navdeep A. Jaikaria · Director
  • Richard A. Cowell · Director
  • Robert L. Martuza · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Gilford Securities Incorporated (CRD 8076) · New York, New YorkSold in NY

Remarks in the notice

  • On fees: “Sales commission consisted of $46,550 and 36-month warrant to purchase 42,318 shares of common stock at exercise price of $1.50 per share.”
  • On the use of proceeds: “All of the proceeds are being added to issuer's working capital which may in the future be used to pay salaries and fees of officers and directors.”

Signed by Manish Singh, Ph.D., President & CEO. Source: SEC Form D, newest notice filed Jun 3, 2010. Read the notice at the SEC.

equitySEC
Mar 2010$2 MNo. 1Under $2 million

ImmunoCellular Therapeutics, Ltd.: Raise no. 1, Mar 2010

Investors in this round

18 investors had bought by the notice of Apr 13, 2010: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them, other: Sold in units with each unit consisting of 1 share of common stock and warrant for .4 share of common stock.
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
$34,800
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • C. Kirk Peacock · Executive Officer
  • James Kirk Bender · Executive Officer
  • Manish Singh · Executive Officer, Director
  • Jacqueline Kirk Brandwynne · Director
  • John L. Yu · Director
  • Navdeep A. Jaikaria · Director
  • Richard A. Cowell · Director
  • Robert L. Martuza · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Scarsdale Equities LLC (CRD 134602) · New York, New YorkSold in NY

Remarks in the notice

  • On fees: “Sales commission consisted of $34,800 and 26-month warrant to purchase 104,400 shares of common stock at exercise price of $1.15 per share.”

Signed by Manish Singh, Ph.D., President & CEO. Source: SEC Form D, newest notice filed Apr 13, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • ImmunoCellular Therapeutics, Ltd. had no revenue when it filed its newest notice of a funding round (Mar 2011).

    SEC Form D (revenue range) · Mar 2011

  • Revenue range over time, as stated in its notices: revenue of up to $1 million in 2010; no revenue in 2011.

    SEC Form D (revenue range) · Mar 2011

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Mar 2011

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of ImmunoCellular Therapeutics, Ltd. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 41 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by ImmunoCellular Therapeutics, Ltd.
NameRoleNamed in
C. Kirk PeacockExecutive officerMar 2011
James Kirk BenderExecutive officerMar 2011
Manish SinghExecutive officerMar 2011
Jacqueline Kirk BrandwynneDirectorMar 2011
John S. YuDirectorMar 2011
Manish SinghDirectorMar 2011
Navdeep A. JaikariaDirectorMar 2011
Rahul A. SinghviDirectorMar 2011
Richard A. CowellDirectorMar 2011
John L. YuDirectorJun 2010
Robert L. MartuzaDirectorJun 2010